Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Health Reference Charts
Type 2 Medications Archives
Print | Email | Share | Comments (0)

Study Will Compare Avandia’s Effect on Treatment of Type 2 Complications

Jan 1, 2000

SmithKline Beecham recently announced plans to initiate a major study to determine if early treatment with Avandia, Glucophage or a sulfonylurea improves and maintains blood sugar control in patients with type 2 diabetes, delays and/or prevents complications such as kidney disease and prevents decline in pancreatic beta-cell function.

According to a SmithKline Beecham news release, the study, called A Diabetes Outcome Progression Trial (ADOPT), will directly compare Avandia to Glucophage or a sulfonylurea. Glucophage and sulfonylureas are traditionally used medications that treat the symptoms of type 2 diabetes. They do not, however, directly target insulin resistance. The ADOPT study will be one of the longest and largest studies of people with type 2 diabetes initiated since the United Kingdom Prospective Diabetes Study.

This phase IV, randomized, double-blind, four-year study will be conducted in 300 sites worldwide and will enroll more than 3,500 recently diagnosed people with type 2 diabetes who have not been previously treated with an oral antidiabetes medication. Patients will be randomized to one of three treatment groups: Avandia, Glucophage or glyburide (glibenclamide in Europe).

The primary objective of the study is to evaluate and compare the metabolic effects of long-term treatment in patients with recently diagnosed type 2 diabetes. Endpoints include the long-term effects of each drug on:

  • Durability of improvement in blood sugar control;
  • Maintenance and restoration of pancreatic beta-cell function and effects on insulin sensitivity;
  • Long-term safety, including liver, cardiovascular and hematological safety;
  • Progression of microalbuminuria, which is an indicator of kidney disease and a cardiovascular risk factor;
  • Other cardiovascular risk factors, including PAI-1, fibrinogen and C-reactive protein;
  • Quality-of-life and pharmacoeconomic profiles.

Categories: Blood Sugar, Diabetes, Insulin, Medications Research, Type 2 Issues, Type 2 Medications



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Jan 1, 2000

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.